This study aimed to evaluate the economic value for leuprorelin acetate 6-month depot compared with leuprorelin acetate 3-month depot from societal perspective in Japanese prostate cancer patients.
In the cost analysis, we estimated the reduction in direct and indirect costs as well as intangible costs saved by having one less injection.